Carole Vuillerot

List of Publications by Year
in descending order

43 papers	1,823 citations	516710 16 h-index	276875 41 g-index
49 all docs	49 docs citations	49 times ranked	1792 citing authors

#	Article	IF	Citations
1	Perceived impact of lockdown on daily life in children with physical disabilities and their families during the COVIDâ€19 pandemic. Child: Care, Health and Development, 2022, 48, 942-955.	1.7	16
2	Implementation of Motor Function Measure score percentile curves - Predicting motor function loss in Duchenne muscular dystrophy. European Journal of Paediatric Neurology, 2022, 36, 78-83.	1.6	6
3	Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Neurology, The, 2022, 21, 42-52.	10.2	89
4	Respiratory management of spinal muscular atrophy type 1 patients treated with Nusinersen. Pediatric Pulmonology, 2022, 57, 1505-1512.	2.0	5
5	Emerging health challenges for children with physical disabilities and their parents during the COVID-19 pandemic: The ECHO French survey. Annals of Physical and Rehabilitation Medicine, 2021, 64, 101429.	2.3	120
6	Responsiveness and Minimal Clinically Important Difference of the Motor Function Measure in Collagen VI-Related Dystrophies and Laminin Alpha2-Related Muscular Dystrophy. Archives of Physical Medicine and Rehabilitation, 2021, 102, 604-610.	0.9	5
7	Elementary visuospatial perception deficit in children with neurodevelopmental disorders. Developmental Medicine and Child Neurology, 2021, 63, 457-464.	2.1	7
8	Understanding the relationship between the 32-item motor function measure and daily activities from an individual with spinal muscular atrophy and their caregiversâ€™ perspective: a two-part study. BMC Neurology, 2021, 21, 143.	1.8	6
9	E-Health & Innovation to Overcome Barriers in Neuromuscular Diseases. Report from the 1st eNMD Congress: Nice, France, March 22-23, 2019. Journal of Neuromuscular Diseases, 2021, 8, 743-754.	2.6	2
10	A Patient-Centered Evaluation of Meaningful Change on the 32-Item Motor Function Measure in Spinal Muscular Atrophy Using Qualitative and Quantitative Data. Frontiers in Neurology, 2021, 12, 770423.	2.4	6
11	Determining the Interrater Reliability of the SOFMER Activity Score (version 2) for Individuals in Rehabilitation Centers. Archives of Physical Medicine and Rehabilitation, 2021, , .	0.9	0
12	Validation of a simple screening test for elementary visuo-spatial perception deficit. Annals of Physical and Rehabilitation Medicine, 2020, 63, 302-308.	2.3	4
13	Cross-cultural Adaptation and Multi-centric Validation of the Motor Function Measure Chinese Version (MFM-32-CN) for Patients with Neuromuscular Diseases. Developmental Neurorehabilitation, 2020, 23, 210-217.	1.1	4
14	Validity and Reliability of the 32-Item Motor Function Measure in 2- to 5-Year-Olds with Neuromuscular Disorders and 2- to 25-Year-Olds with Spinal Muscular Atrophy. Neurology and Therapy, 2020, 9, 575-584.	3.2	18
15	Assessment of the validity and reliability of the 32-item Motor Function Measure in individuals with Type 2 or non-ambulant Type 3 spinal muscular atrophy. PLoS ONE, 2020, 15, e0238786.	2.5	9
16	Long-term follow-up of patients with type 2 and non-ambulant type 3 spinal muscular atrophy (SMA) treated with olesoxime in the OLEOS trial. Neuromuscular Disorders, 2020, 30, 959-969.	0.6	15
17	From singular to holistic: Approaches in pediatric rehabilitation medicine for children with cerebral palsy. Annals of Physical and Rehabilitation Medicine, 2020, 63, 391-392.	2.3	3
18	Effects of nusinersen after one year of treatment in 123 children with SMA type 1 or 2: a French real-life observational study. Orphanet Journal of Rare Diseases, 2020, 15, 148.	2.7	63

#	Article	IF	Citations
19	State of the art for motor function assessment tools in spinal muscular atrophy (SMA). Archives De Pediatrie, 2020, 27, 7S40-7S44.	1.0	5
20	Longitudinal changes in clinical outcome measures in COL6-related dystrophies and LAMA2-related dystrophies. Neurology, 2019, 93, e1932-e1943.	1.1	23
21	Hand Dexterity: Design for Automatic Evaluation of Item 18 of MFM Scale. Procedia CIRP, 2019, 84, 514-519.	1.9	1
22	Motor function performance in individuals with RYR1 â€related myopathies. Muscle and Nerve, 2019, 60, 80-87.	2.2	5
23	Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscular Disorders, 2018, 28, 103-115.	0.6	584
24	Congenital Titinopathy: Comprehensive characterization and pathogenic insights. Annals of Neurology, 2018, 83, 1105-1124.	5.3	93
25	Is Going Beyond Rasch Analysis Necessary to Assess the Construct Validity of a Motor Function Scale?. Archives of Physical Medicine and Rehabilitation, 2018, 99, 1776-1782.e9.	0.9	8
26	Corticosteroids in Duchenne muscular dystrophy: impact on the motor function measure sensitivity to change and implications for clinical trials. Developmental Medicine and Child Neurology, 2018, 60, 185-191.	2.1	19
27	Construction and feasibility study of the SOFMER Activity Score (SAS), a new assessment of physical and cognitive activity. Annals of Physical and Rehabilitation Medicine, 2018, 61, 315-322.	2.3	2
28	Prospective and longitudinal natural history study of patients with Type 2 and 3 spinal muscular atrophy: Baseline data NatHis-SMA study. PLoS ONE, 2018, 13, e0201004.	2.5	107
29	Mathematical Disease Progression Modeling in Type 2/3 Spinal Muscular Atrophy. Muscle and Nerve, 2018, 58, 528-535.	2.2	1
30	Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurology, The, 2017, 16, 513-522.	10.2	95
31	User-Centered Development of an Information System in Patientâ€™s Motor Capacity Evaluation. Springer Proceedings in Mathematics and Statistics, 2017, , 121-131.	0.2	1
32	The motor function measure to study limitation of activity in children and adults with Charcot-Marie-Tooth disease. Annals of Physical and Rehabilitation Medicine, 2014, 57, 587-599.	2.3	7
33	Influence of a two-year steroid treatment on body composition as measured by dual X-ray absorptiometry in boys with Duchenne muscular dystrophy. Neuromuscular Disorders, 2014, 24, 467-473.	0.6	12
34	Rasch Analysis of the Motor Function Measure in Patients With Congenital Muscle Dystrophy and Congenital Myopathy. Archives of Physical Medicine and Rehabilitation, 2014, 95, 2086-2095.	0.9	16
35	Quality of life and functional outcome in early school-aged children after neonatal stroke: A prospective cohort study. European Journal of Paediatric Neurology, 2014, 18, 347-353.	1.6	9
36	English Cross-Cultural Translation and Validation of the Neuromuscular Score: A System for Motor Function Classification in Patients With Neuromuscular Diseases. Archives of Physical Medicine and Rehabilitation, 2014, 95, 2064-2070.e1.	0.9	11

#	Article	IF	Citations
37	Responsiveness of the Motor Function Measure in Patients With Spinal Muscular Atrophy. Archives of Physical Medicine and Rehabilitation, 2013, 94, 1555-1561.	0.9	73
38	Development and validation of a motor function classification in patients with neuromuscular disease: The NM-Score. Annals of Physical and Rehabilitation Medicine, 2013, 56, 673-686.	2.3	6
39	Motor Function Measure: Validation of a Short Form for Young Children With Neuromuscular Diseases. Archives of Physical Medicine and Rehabilitation, 2013, 94, 2218-2226.	0.9	63
40	Responsiveness of the Motor Function Measure in Neuromuscular Diseases. Archives of Physical Medicine and Rehabilitation, 2012, 93, 2251-2256.e1.	0.9	46
41	Motor and respiratory heterogeneity in Duchenne patients: Implication for clinical trials. European Journal of Paediatric Neurology, 2012, 16, 149-160.	1.6	112
42	Monitoring changes and predicting loss of ambulation in Duchenne muscular dystrophy with the Motor Function Measure. Developmental Medicine and Child Neurology, 2010, 52, 60-65.	2.1	114
43	Self-Perception of Quality of Life by Adolescents with Neuromuscular Diseases. Journal of Adolescent Health, 2010, 46, 70-76.	2.5	27